Key Takeaways
- Q4 recovery proves the model: Revenue surged 47% QoQ to ₹428.2 crore and EBITDA more than quintupled as the India Semaglutide launch converted pipeline into commercial reality, though full-year revenue still declined 2% YoY.
- The capacity bet is now live: DDC invoicing began, a second line enters qualification next quarter, and a third arrives later this year, all funded and backed by customer take-or-pay contracts that de-risk the build-out.
- Biologics funnel is scaling fast: The pipeline expanded nearly 4x, with a European biosimilar partner, a US biosimilar major, and a second animal-health project all added this year, setting up meaningful contribution by FY28.
- The scheme deferral removes an overhang but delays consolidation: SEBI approval was in hand, yet smaller-investor pushback on valuation forced a pause; management will revisit in roughly two years.
- What to watch next quarter: Whether the second DDC line commercializes on schedule, the pace of emerging-market approval flow for partners, and any signal on FY27 revenue trajectory now that the India launch is behind us.
Semaglutide: From Pipeline to Commercial Engine
- India launch validated the CDMO thesis: Generic Semaglutide launched at quarter-end with partners present across multiple brands; the customer base as of end-April already holds nearly two-thirds of Indian generic market share by value.
- First-mover lock-in with regulators: OneSource is the first and only CDMO partner for the first three generic Semaglutide approvals in both the US (tentative) and Canada, a position that creates a structural advantage as more approvals flow.
- Canada approvals unlock the next leg: Approvals received for Canada; one partner (Dr. Reddy's, publicly known) and a second (Orbicular, partnered with a large Canadian company) are the only two approved entities in that market. More approvals are in Health Canada's pipeline.
- Emerging markets are the volume story: Post-India approval, several emerging markets will grant approvals to partners; Saudi Arabia launch is imminent now that the Indian patent constraint is gone. Brazil, the largest Semaglutide market outside North America per IQVIA, and Turkey are also in play.
- Demand will outrun supply for years: Management sees the demand-supply gap persisting at least two more years, with the bottleneck on supply, not demand. Customers are locking in access through upfront fees and take-or-pay contracts.
- Oral GLP-1s are not a threat to the injectable franchise: Orals carry efficacy, pill-burden and side-effect disadvantages; the injectable pipeline of next-generation GLP products is overwhelmingly injectable, and management expects orals to capture at most 25-33% of the market.
Neeraj Sharma: "Specifically, on Semaglutide, you know many of your questions would be around that, so specifically here, we have moved in this quarter from pipeline to real proof."
Capacity Build-Out: The $400 Million Foundation
- DDC capacity is scaling in lockstep with demand: The second line is installed and undergoing qualification, available from Q2; the third line comes online later this year, taking the installed base to three lines by FY27-end. Sequential quarterly revenue and EBITDA improvement is built on these additions.
- Batch sizes are upgrading sooner than planned: The first new line is moving to larger batch sizes (750 to 1,000 liters) faster than originally anticipated, increasing throughput without adding lines.
- Customer contracts de-risk the investment: Capacity reservations include upfront fees and take-or-pay commitments; customers are funding the inventory build (₹158 crore to ₹440 crore), making it fungible and risk-free to OneSource.
- Soft gelatin capacity is filling fast: Last year's expansion is absorbing new customers; by end of this year or next, no real capacity will remain. A transition to a new company-owned site will follow the limited-period Strides agreement.
- Beyond FY28, a fourth line and dedicated injectables: A fourth line in unit two will add dedicated injectable capability including high-viscosity pre-filled syringes via SPD, supporting the soft-gels and injectables business trending toward $100 million.
Neeraj Sharma: "right now the biggest challenge actually for the customers is access to capacity. And for them to secure this access, customers have done capacity reservation with us. And that capacity reservation includes blocking capacity and submitting to pick up that capacity both by paying upfront fee as well as take-or-pay kind of contract."
Biologics: The FY28 Growth Wedge
- Funnel expansion is accelerating: The biologics pipeline grew nearly 4x year-on-year, adding a European biosimilar partner, a US biosimilar major, and a second project from a top-three global animal-health company.
- Revenue contribution timeline is firming up: Agreements will be signed across FY27 and FY28; meaningful contribution arrives in FY28, with commercial manufacturing starting beyond FY28, from FY29 onward.
- Management guards customer details tightly: Revenue and EBITDA breakdowns for the biologics segment, and the year of breakeven, were declined on confidentiality grounds, a consistent posture across the call.
Financial Health & the Scheme Pause
- Operating leverage kicked in sharply: Q4 EBITDA of ₹91.9 crore was over 5x the prior quarter, with margins expanding 1,550 bps QoQ on higher CSA revenues, though full-year EBITDA still fell ~35% on the delayed Canadian approvals.
- Working capital build is launch inventory, not a problem: Elevated inventory is fully customer-funded and fungible; normalization is expected during FY27.
- Borrowing costs fell meaningfully: Four notch upgrades since listing drove cost of borrowing below 9%, a 210 bps reduction year-on-year.
- The scheme deferral was a valuation call, not a strategic retreat: SEBI and stock exchanges approved the Steriscience/Brooks scheme on February 26, but smaller-investor concerns on valuation and the drop from the intended ₹2,200 per share listing price led management to pause. Both units will pursue independent growth; re-evaluation comes in roughly two years.
- Staff cost and opex rose to support the ramp: Investments in headcount and other expenses, even as revenue dipped, are tied to capacity expansion, particularly the second DDC line's qualification phase. This opex supports the $400 million revenue guidance.
Arun Kumar: "We didn't get that same comfort this time, although we would have got through majority without difficulties, and we decided to pause this for some more time and come back and discuss this further."
Base Business & Compliance Moat
- Base business stayed active: 10 new licenses signed, over 15 products launched, new customers added, and capabilities expanded at the SPD site to deepen the specialty injectable offering.
- Regulatory track record is a competitive asset: 49 audits completed; surprise FDA inspections at two sites both closed successfully with EIRs; EU GMP certification renewed at flagship and sterile injectable sites; ANVISA approval received.
- EcoVadis Bronze and NSE sustainability leader recognition reinforce the ESG credentials that matter for global pharma procurement.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic revenue target | $400 million with ~40% EBITDA margins | FY28 |
| Second DDC line commercialization | Line undergoing qualification, available for commercial production | Q2 FY27 (next quarter) |
| Third DDC line installation | Third line added, three lines installed total | By end of FY27 |
| Sequential revenue and EBITDA improvement | Quarter-on-quarter growth built on new capacity availability | Throughout FY27 |
| Working capital normalization | Elevated inventory to normalize | During FY27 |
| ROCE target | Build toward 50%+ | Medium term |
| Biologics meaningful contribution | Agreements signed, revenue contribution visible | FY27 and FY28 |
| Biologics commercial manufacturing | Commercial production begins | Beyond FY28, from FY29 |
| Soft gelatin capacity fully utilized | No real capacity available beyond current | End of CY26 or CY27 |
| Scheme re-evaluation | Revisit Steriscience/Brooks consolidation | In roughly two years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹428.2 cr, +47% QoQ |
| Full-year revenue | ₹1,421.6 cr, -2% YoY |
| EBITDA | ₹91.9 cr, more than 5x QoQ |
| EBITDA margin expansion | 1,550 bps QoQ |
| Full-year EBITDA decline | ~35% YoY, due to delayed Semaglutide approvals |
| Adjusted PAT | ~₹39 cr, versus a loss in Q3 |
| Full-year adjusted PAT | ₹73.9 cr |
| EPS (fully diluted) | ₹3.4 |
| Full-year EPS | ₹6.5 |
| Cost of borrowing | Below 9%, 210 bps lower than prior year |
| FY28 organic revenue guidance | US$400 million, with ~40% EBITDA margins, reiterated |
| DDC capacity expansion capex | US$100 million |
| DDC lines installed by end of FY27 | 3 lines, with 675 odd sterile manufacturing days available |
| Biologics funnel expansion | ~4x versus previous year |
| Regulatory and customer audits completed in FY26 | 49 |